Filing Details

Accession Number:
0000899243-22-002693
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-01-20 18:14:50
Reporting Period:
2022-01-18
Accepted Time:
2022-01-20 18:14:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1534120 Avalo Therapeutics Inc. AVTX Pharmaceutical Preparations (2834) 450705648
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1601086 Armistice Capital, Llc 510 Madison Avenue, 7Th Floor
New York NY 10022
Yes No Yes No
1633584 Ltd. Fund Master Capital Armistice 510 Madison Avenue
7Th Floor
New York NY 10022
Yes No Yes No
1706140 Steven Boyd 510 Madison Avenue
7Th Floor
New York NY 10022
Yes No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-01-18 206,300 $0.88 46,306,300 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-01-19 93,700 $0.88 46,400,000 No 4 P Indirect See Footnote
Common Stock Acquisiton 2022-01-20 12,000 $0.85 46,412,000 No 4 P Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 412,442 Direct
Footnotes
  1. The reported securities of Avalo Therapeutics, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
  2. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8762 to $0.9029, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8501 to $0.8956, inclusive.
  4. These shares are directly owned by Mr. Boyd in his personal capacity.